Thus, current PSA screening is not cost-effective from a public health perspective [3] and many urologists are concerning for over-diagnosis of PCa with widespread serum PSA screening, which eventually could lead to overtreatment of PCa and its accompanied morbidities. This evidence concerns the gene KLK3 and posterior cortical atrophy.